Literature DB >> 22129056

Type I interferonopathies: a novel set of inborn errors of immunity.

Yanick J Crow1.   

Abstract

The concept of grouping Mendelian disorders associated with an upregulation of type I interferon is not currently recognized in the medical literature. Here, we argue that such a concept has scientific validity and clinical utility. Specifically, we discuss a group of conditions, including Aicardi-Goutières syndrome, spondyloenchondrodysplasia, and cases of systemic lupus erythematosus with complement deficiency, in which an upregulation of type I interferons is apparently central to their pathogenesis. We believe that these diseases can usefully be considered to represent a novel set of inborn errors of immunity, and that the recognition of such diseases as type I interferonopathies will have significance in the development and use of targeted therapies.
© 2011 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129056     DOI: 10.1111/j.1749-6632.2011.06220.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  155 in total

Review 1.  [Type I interferonopathies. Systemic inflammatory diseases triggered by type I interferons].

Authors:  C Günther; F Schmidt; N König; M A Lee-Kirsch
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

2.  Tracking interferon in autoimmunity.

Authors:  Virginia Pascual; Jacques Banchereau
Journal:  Immunity       Date:  2012-01-27       Impact factor: 31.745

Review 3.  Intracellular Nucleic Acid Detection in Autoimmunity.

Authors:  John T Crowl; Elizabeth E Gray; Kathleen Pestal; Hannah E Volkman; Daniel B Stetson
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

Review 4.  Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.

Authors:  Romain Banchereau; Alma-Martina Cepika; Jacques Banchereau; Virginia Pascual
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

Review 5.  Monogenic autoinflammatory diseases: disorders of amplified danger sensing and cytokine dysregulation.

Authors:  Gina A Montealegre Sanchez; Adriana Almeida de Jesus; Raphaela Goldbach-Mansky
Journal:  Rheum Dis Clin North Am       Date:  2013-09-21       Impact factor: 2.670

Review 6.  Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies.

Authors:  Maroof Hasan; Nan Yan
Journal:  Pharmacol Res       Date:  2016-06-25       Impact factor: 7.658

7.  The Akt1 isoform is required for optimal IFN-β transcription through direct phosphorylation of β-catenin.

Authors:  Benjamin N Gantner; Huali Jin; Feng Qian; Nissim Hay; Bin He; Richard D Ye
Journal:  J Immunol       Date:  2012-08-17       Impact factor: 5.422

8.  Genetic, Phenotypic, and Interferon Biomarker Status in ADAR1-Related Neurological Disease.

Authors:  Gillian I Rice; Naoki Kitabayashi; Magalie Barth; Tracy A Briggs; Annabel C E Burton; Maria Luisa Carpanelli; Alfredo M Cerisola; Cindy Colson; Russell C Dale; Federica Rachele Danti; Niklas Darin; Begoña De Azua; Valentina De Giorgis; Christian G L De Goede; Isabelle Desguerre; Corinne De Laet; Atieh Eslahi; Michael C Fahey; Penny Fallon; Alex Fay; Elisa Fazzi; Mark P Gorman; Nirmala Rani Gowrinathan; Marie Hully; Manju A Kurian; Nicolas Leboucq; Jean-Pierre S-M Lin; Matthew A Lines; Soe S Mar; Reza Maroofian; Laura Martí-Sanchez; Gary McCullagh; Majid Mojarrad; Vinodh Narayanan; Simona Orcesi; Juan Dario Ortigoza-Escobar; Belén Pérez-Dueñas; Florence Petit; Keri M Ramsey; Magnhild Rasmussen; François Rivier; Pilar Rodríguez-Pombo; Agathe Roubertie; Tommy I Stödberg; Mehran Beiraghi Toosi; Annick Toutain; Florence Uettwiller; Nicole Ulrick; Adeline Vanderver; Amy Waldman; John H Livingston; Yanick J Crow
Journal:  Neuropediatrics       Date:  2017-04-10       Impact factor: 1.947

9.  Type I interferons link viral infection to enhanced epithelial turnover and repair.

Authors:  Lulu Sun; Hiroyuki Miyoshi; Sofia Origanti; Timothy J Nice; Alexandra C Barger; Nicholas A Manieri; Leslie A Fogel; Anthony R French; David Piwnica-Worms; Helen Piwnica-Worms; Herbert W Virgin; Deborah J Lenschow; Thaddeus S Stappenbeck
Journal:  Cell Host Microbe       Date:  2014-12-04       Impact factor: 21.023

10.  JAK1 Inhibition Blocks Lethal Immune Hypersensitivity in a Mouse Model of Down Syndrome.

Authors:  Kathryn D Tuttle; Katherine A Waugh; Paula Araya; Ross Minter; David J Orlicky; Michael Ludwig; Zdenek Andrysik; Matthew A Burchill; Beth A J Tamburini; Colin Sempeck; Keith Smith; Ross Granrath; Dayna Tracy; Jessica Baxter; Joaquin M Espinosa; Kelly D Sullivan
Journal:  Cell Rep       Date:  2020-11-17       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.